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Background: Recombinant activated factor VII (rFVIIa, NovoSeven®) was introduced in 1996 
for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.
Objective: To review the evidence supporting the use of rFVIIa for the treatment of patients 
with congenital bleeding disorders.
Patients and methods: English-language databases were searched in September 2009 for 
reports of randomized controlled trials (RCTs) evaluating the ability of rFVIIa to restore hemo-
stasis in patients with congenital bleeding disorders.
Results: Eight RCTs involving 256 hemophilic patients with antibodies against coagulation 
factors, also known as inhibitors, were identified. The evidence supporting the use of rFVIIa in 
these patients was weak with regard to dose, clinical setting, mode of administration, efficacy, 
and adverse events, given the limited sample size of each RCT and the heterogeneity of the 
studies.
Conclusion: The authors suggest that rFVIIa therapy in hemophilic patients with inhibitors 
should be based on the individual’s ability to generate thrombin and form a clot, and not on the 
patient’s weight alone. Therefore, assays for thrombin generation, such as whole-blood throm-
boelastography, have the potential to significantly improve the treatment of these patients.
Keywords: hemophilia, inhibitors, coagulation factor VIII, coagulation factor IX, rFVIIa, 
NovoSeven, FEIBA, hemostasis, RCT
Introduction
Hemophilic patients are subject to recurrent bleeding episodes that are associated 
with pain and disability; the most common type is musculoskeletal bleeding. Despite 
improvements in therapy, patients with severe hemophilia have a significantly 
reduced life expectancy, primarily due to liver disease, hepatocellular carcinoma, and 
  intracranial hemorrhage.1
Some patients with hemophilia develop neutralizing, high-affinity polyclonal 
immunoglobulin G antibodies against the replaced coagulation factors. Such neutral-
izing antibodies are commonly known as inhibitors because they inactivate factors VIII 
(FVIII) and IX (FIX), with a higher incidence reported in hemophilia A than in hemo-
philia B.2 Specifically, the reported prevalence of inhibitor expression in patients with 
hemophilia A varies from 3.6%3 to 32%.4 Many reasons for this wide range have been 
suggested, including variation in the proportion of moderately and severely affected 
patients, the therapeutic regimen (prophylactic vs therapeutic), the type of concentrate 
administered, the viral inactivation method used during production, and the method 
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also depends on the length of exposure to FVIII, the age at 
the time of first exposure, and the genetic background of 
the patient.2 There is a close correlation between mutation 
type and inhibitor development, so patients with less severe 
mutations have a lower likelihood of inhibitor expression 
than patients possessing severe mutations.5
The development of inhibitors is one of the most serious 
challenges in coagulation-factor replacement therapy and 
a major cause of morbidity and mortality in patients with 
hemophilia.6 The prophylactic use of FVIII in these patients 
is impractical, and the treatment of acute bleeding is difficult 
because the inhibitors hasten neutralization of infused FVIII, 
rendering it partially or completely ineffective. Additionally, 
elective surgery is rarely undertaken as the inhibitors make it 
difficult or even impossible to restore hemostasis during the 
perioperative period. Patients with low-titer, low-responding 
inhibitors (ie, peak titers ,5 Bethesda Units [BU]/mL) face 
fewer clinical problems because hemostasis usually can be 
achieved by saturating the inhibitor with higher doses of 
the deficient factor. However, in patients presenting with 
high-titer, high-responding inhibitors (.5 BU/mL), the 
coagulation factor will be neutralized. As a result, other 
treatment modalities that diminish the levels of inhibitors (eg, 
plasmapheresis, immunoabsorption, and immune tolerance 
induction) and/or bypass their activity must be used.
FVIII inhibitor bypassing agent (FEIBA), specifically by 
an activated prothrombin complex concentrate (aPCC), has 
been used for decades as a hemostasis-bypassing agent in 
patients with high-responding inhibitors.7 Porcine FVIII is 
also efficacious in most patients with hemophilia A presenting 
moderate to high inhibitor titers, although its use has been lim-
ited by allergic transfusion reactions, thrombocytopenia, and 
brisk anamnesis.2 Recombinant activated factor VII (rFVIIa, 
NovoSeven®; Novo Nordisk A/S, Bagsværd,   Denmark) was 
introduced in 1996 for the treatment of hemophilic patients 
with antibodies against FVIII or FIX. This agent was ini-
tially approved for the treatment of spontaneous or surgical 
bleeds in patients with inhibitors, with a recommended 
dosing schedule of 90 µg/kg rFVIIa every 2–3 hours until 
achievement of hemostasis.8 Then, in 2007, the European 
Medicines Agency (EMEA) approved the use of single-dose 
rFVIIa (270 µg/kg) to address mild to moderate bleeds in 
inhibitor-expressing patients with hemophilia.9 rFVIIa is cur-
rently a first-line therapy for bleeding episodes in patients 
with congenital hemophilia A or B who express antibodies 
against coagulation factors and is also used to treat patients 
with acquired hemophilia.10–12 In Europe, rFVIIa has also 
been approved for the treatment of patients with congenital 
FVII deficiency or Glanzmann’s thrombasthenia, which may 
be refractory to platelet transfusion.
The administration of pharmacological doses of rFVIIa 
(ie, plasma concentrations of 25 nM, corresponding to 
90 µg/kg dosing or higher) induces hemostasis in the absence 
of FVIII or FIX. The underlying mechanism is probably 
the enhancement of thrombin generation on the surface of 
thrombin-activated platelets, leading to a stable, near-normal 
fibrin clot network containing thin fibrin fibers and tightly 
packed fibrin strands that form a strong hemostatic plug.8 In 
a cell-based  in vitro model of hemostasis, it was shown that 
rFVIIa binds to the thrombin-activated platelet surface with 
low affinity and that this binding requires higher concentra-
tions of rFVIIa than those found normally in circulating 
blood. The bound rFVIIa activates factor X (FX) on the 
activated platelet surface, independent of the presence of 
FVIII or FIX.13 Also, rFVIIa inhibits fibrinolysis  in vitro in 
hemophilia A plasma, thus prolonging the clot lysis time by 
inducing thrombin-activatable fibrinolysis inhibitor (TAFI). 
However, higher rFVIIa levels are still required to normalize 
fibrinolysis compared with the levels required to normal-
ize clot formation.14 The hemostatic effect of exogenously 
administered rFVIIa at pharmacological doses is, thus, medi-
ated by a combination of several factors, including enhanced 
thrombin generation rate, increased platelet activation and 
adhesion, and full activation of TAFI and FXIII.
This review presents evidence supporting the use of 
rFVIIa to treat congenital bleeding disorders with regard to 
dose, clinical setting (home vs hospital), mode of administra-
tion, indication (therapeutic vs prophylactic), efficacy, and 
adverse events.
Methods
English-language databases including MEDLINE, Science-
Direct, CINAHL, and Blackwell Science were searched in 
September 2009 for reports of randomized controlled trials 
(RCTs) testing the effect of rFVIIa on hemostasis in patients 
with congenital hemophilia A or B, congenital FVII defi-
ciency, or Glanzmann’s thrombasthenia. The keywords used, 
both individually and in combination, were recombinant 
activated factor VII, recombinant factor VIIa, recombinant 
FVIIa, rFVIIa, and NovoSeven®. Hits using these keywords 
were cross-referenced with the terms used in clinical trial, 
randomized clinical trial, clinical study, randomized clini-
cal study, and placebo-controlled study. References in the 
resultant articles were cross-checked for other potentially 
relevant studies. The inclusion criteria were as follows: 
(1) prospective, randomized trial; (2) use of rFVIIa; and Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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(3) presence of a control group (placebo, other hemostatic 
agent, or a different dose of rFVIIa). The following studies 
were not included: (1) studies lacking a control group or 
randomization; (2) retrospective studies; (3) studies involving 
off-label use of rFVIIa; and (4) studies of rFVIIa combined 
with other hemostatic compounds. The end results of inter-
est were achievement of hemostasis and development of 
thromboembolic adverse events.
Results
Eight RCTs involving 256 patients, who received study 
medication, were identified (Table 1). Two trials evaluated 
the effect of rFVIIa compared with FEIBA and 6 investigated 
the impact of different doses of rFVIIa (1 assessed prophy-
lactic use and 1 evaluated the effect of bolus administration 
of rFVIIa compared with continuous infusion [CI]).
Hemophilia coupled with  
coagulation-factor inhibitors
The first study examined was performed by Shapiro et al.15 
This prospective, double-blind study compared the outcomes 
of 35 and 90 µg/kg rFVIIa administered during and after 
elective surgery in patients with hemophilia. The patients 
received rFVIIa immediately before incision,   intraoperatively 
Table 1 Randomized clinical trials concerning rFviia in hemophilia patients with inhibitors
Study Type Intervention No  
treated
Response to  
treatment
Thrombotic  
adverse event
Shapiro et al15  
{1735}
Double-blind RCT rFviia 35 vs 90 µg/kg before  
incision, then every 2 h or as 
needed for 48 h, then every  
2–6 h for 3 d, thereafter  
90 µg/kg as needed
29 Treatment successful: low  
dose 67% vs high dose 93%,  
being significant from day 3  
postoperatively, P , 0.05
1 in the  
35 µg/kg group
Lusher et al11  
{1730}
Double-blind RCT rFviia 35 vs 70 µg/kg to  
treat joint, muscle, and  
mucocutaneous bleedings
66 Treatment rated excellent in  
61% (35 µg/kg⋅group) vs 57%  
(70 µg/kg⋅group), P = NS
None
Santagostino et al16  
{1734}
Multicenter, open-label, 
crossover RCT
rFviia 270 vs 90 µg/kg within  
6 h of joint bleed every 3 h;  
if not hemostasis at 9 h Ci, 
90 µg/kg up to 24 h, then  
other options
18 Hemostasis at 9 h 25% (high  
dose) vs 31% low dose,  
P = NS; number of Bis needed  
in the high-dose (n = 1) vs  
standard-dose (n = 3) groups,  
P = 0.0001
None
Kavakli et al17  
{1695}
Multicenter, double-blind, 
crossover RCT
rFviia 270 µg/kg + 0 + 0 at 3-h  
intervals vs 3 × 90 µg/kg at 3-h  
intervals at first and second  
joint bleeding, or vice versa
22 65% (270 µg/kg) vs 70%  
(3 × 90 µg/kg) achieved  
hemostasis, P = NS
None
Astermark et al18  
{1710}
Multicenter, open-label, 
crossover RCT
1 dose of FeiBA  
(75–100 iU/kg) vs 2 doses  
of rFviia 90–120 µg/kg
48 FeiBA (80.9%) and rFviia  
(78.7%) exhibit similar effects  
on joint bleeds, P = 0.059
None
Konkle et al19  
{1729}
Double-blind,  
crossover RCT
rFviia 270 vs 90 µg/kg daily  
prophylaxis for 3 mo compared  
with 3 mo preprophylactic and  
postprophylactic periods
22 Reduced bleeding frequency  
by 45% (90 µg/kg) and 59%  
(270 µg/kg), both P , 0.001; no  
difference between dose groups
None
Pruthi et al20  
{1736}
Multicenter,  
open-label RCT
Preoperative bolus dose of  
90 µg/kg and Bi every 2 h  
during surgery till POD 5.  
Then every 4 h till POD 10 vs  
Ci 50 µg/kg/h till POD 5  
and then 25 µg/kg/h till POD 10
24 Hemostatic efficacy was 73%  
in Bi vs 75% in Ci, P = NS
1 in the Bi 
group
Young et al21  
{1719}
Multicenter, double-blind, 
crossover RCT
270 µg/kg + 0 + 0 every  
3 h vs 3 × 90 µg/kg vs 75 iU/kg  
FeiBA at time 0
27 Rescue medication needed  
within 9 h was 8.3% (rFviia  
270 µg/kg), 9.3% (3 × 90 µg/kg)  
and 36.4% (FeiBA), respectively;  
rFviia 270 and 3 × 90 µg/kg vs  
FeiBA, P = 0.032 and P = 0.069,  
respectively; no difference  
between rFviia dose groups
None
Abbreviations: Bi, bolus infusion; Ci, continuous infusion; POD, postoperative day; FeiBA, factor eight inhibitor bypassing agent; aPCC, activated prothrombin complex 
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as needed, every 2 hours for the first 48 hours and every 
2–6 hours for the following 3 days. After day 5, open-label 
rFVIIa (90 µg/kg) was available for the maintenance of 
hemostasis. Intraoperative hemostasis was achieved in 28 
of 29 patients. All high-dose-treated patients and 12 of 
15 low-dose-treated patients achieved satisfactory hemo-
stasis over the first 48 hours after surgery. In 1 patient who 
had received the dose of 35 µg/kg rFVIIa, thrombosis of 
the right internal jugular vein developed on the second day 
following central venous catheter placement. The median 
total amount of rFVIIa administered was similar between the 
low-dose- and high-dose-treated groups, despite the reduction 
in the number of days of dosing required in surgical patients 
receiving the high dose. However, a statistically significant 
difference in efficacy from postoperative day 3 to 5 was 
reported, favoring the high-dose-treated group.
In a randomized, double-blind study, Lusher et al11 inves-
tigated the effect of 35 and 70 µg/kg rFVIIa on hemostasis 
in hemophilia A and B patients with joint, muscular, and 
mucocutaneous bleeding and with or without the expression 
of coagulation-factor inhibitors. The results indicated that 
35 µg/kg rFVIIa was statistically equivalent to the dose of 
70 µg/kg rFVIIa with regard to hemostatic efficacy. Addition-
ally, no thromboembolic adverse events were reported.
Santagostino et al16 reported a randomized multicenter, 
open-label, prospective crossover trial comparing the effi-
cacy and safety of standard-dose (90 µg/kg every 3 hours, 
as needed) and high-dose (single dose of 270 µg/kg) rFVIIa 
for at-home treatment of 4 consecutive hemarthroses in 
18 hemophilic patients with inhibitors. Patients not achiev-
ing hemostasis within 9 hours continued rFVIIa treatment 
in the form of repeated standard doses. Success rates for 
standard- and high-dose regimens were similar (31% and 
25% at 9 hours and 66% and 64% at 48 hours, respectively). 
The median number of rFVIIa infusions needed to achieve 
hemostasis was significantly greater for the standard-dose 
(n = 3) than for the high-dose regimen (n = 1, P = 0.0001). 
Moreover, no thromboembolic events were reported.
A similar study, involving the at-home treatment of joint 
bleeds, was performed by Kavakli et al.17 In this multicenter, 
crossover, double-blind trial, patients were randomly selected 
to receive treatment for first joint bleed with a single dose 
of 270 µg/kg rFVIIa followed by 2 doses of placebo at 
3-hour intervals and treatment for second joint bleed with 
3 single doses of 90 µg/kg rFVIIa at 3-hour intervals, or vice 
versa. Efficacy was evaluated using a treatment-response 
rating scale based on the patient’s assessment of pain and 
joint mobility. Treatment was rated as effective for 65% of 
patients’ receiving a single dose of 270 µg/kg and for 70% 
of patients receiving the triple dose of 90 µg/kg (P = 0.67), 
and no thromboembolic events were reported.
Astermark et al18 reported a randomized comparison 
of efficacy in patients treated with a single dose of FEIBA 
(75–100 IU/kg body weight; target dose, 85 IU/kg) and 
in patients treated with 2 doses of rFVIIa (90–120 µg/kg; 
target dose, 105 µg/kg × 2), with the second dose of rFVIIa 
administered 2 hours after the first. The hemostatic effect 
of the treatment was evaluated in patients after 2, 6, 12, 24, 
36, and 48 hours. No significant differences between the 2 
treatment groups were identified at any time point, although 
FEIBA treatment was consistently associated with the highest 
efficacy ratings. Efficacy at 6 hours was 80.9% in FEIBA-
treated and 78.7% in rFVIIa-treated patients (P = 0.059), and 
no thromboembolic events were reported.
A randomized clinical trial examining rFVIIa for second-
ary prophylaxis in hemophilic patients with coagulation-
factor inhibitors was reported by Konkle et al.19 Thirty-eight 
patients entered a 3-month preprophylaxis period to confirm 
high baseline bleeding frequency (mean, $4 bleeds per 
month). Twenty-two patients were randomized at a 1:1 ratio 
to receive daily rFVIIa prophylaxis at either 90 or 270 µg/kg 
for 3 months, followed by a 3-month postprophylaxis period. 
Bleeding frequency was reduced by 45% and 59% during 
prophylaxis with 90 and 270 µg/kg rFIIVa, respectively (both 
P , 0.0001), and remained reduced during the postprophy-
laxis period. Patients reported significantly fewer hospital 
admissions and days absent from work or school during 
prophylaxis when compared with the preprophylaxis period. 
No significant differences were detected between the 2 doses, 
and no thromboembolic events were reported.
Pruthi et al20 investigated the efficacy of bolus infusion 
(BI) vs CI of rFVIIa in inhibitor-expressing hemophilia A and 
B patients undergoing major surgery. Safety was compared 
with that in a control group of patients lacking inhibitors and 
receiving FVIII or FIX concentrates before major surgery. 
All inhibitor-expressing patients received an initial bolus of 
90 µg/kg rFVIIa and were then randomly assigned to the BI 
(n = 12) or CI (n = 12) group. The BI group received 90 µg/kg 
rFVIIa every 2 hours during surgery till day 5, followed by 
90 µg/kg rFVIIa every 4 hours from day 6 to 10. Meanwhile, 
the CI group received 50 µg/kg rFVIIa every hour till day 5, 
followed by 25 µg/kg rFVIIa every hour from day 6 to 10. The 
hemostatic efficacy of rFVIIa in each treatment group was 
comparable, with efficacy demonstrated in 8 of 11 (73%) and 
9 of 12 (75%) subjects in the BI and CI groups, respectively, 
and inefficacy observed in 3 subjects per group.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Young et al21 evaluated the efficacy and safety of rFVIIa 
and FEIBA treatments for controlling joint bleeds in an 
at-home treatment setting. Patients received each of 3 treat-
ments in 1 of 6 possible sequences: (1) 270 µg/kg rFVIIa at 
hour 0 plus placebo at hours 3 and 6; (2) 90 µg/kg rFVIIa at 
hours 0, 3, and 6; and (3) 75 IU/kg FEIBA at hour 0. Efficacy 
was assessed based on the need for rescue treatment within 
9 hours of administration of the trial drugs. The percentage 
of patients treated with 270 µg/kg rFVIIa, who required 
additional hemostatic treatment within 9 hours (8.3%), was 
significantly lower than that of the FEIBA-treated group 
(36.4%, P = 0.032), whereas the percentage of patients treated 
with 90 µg/kg rFVIIa, who required such rescue medication 
(9.1%, P = 0.07), was not significantly lower than that of the 
FEIBA-treated group. Throughout the study, no safety issues 
were identified.
Thrombophilia and acquired  
FVIIa deficiency
No randomized controlled studies conducted in patients with 
Glanzmann’s thrombasthenia, Bernard Souliers syndrome, or 
acquired FVIIa deficiency were identified.
Discussion
This review identified 8 randomized clinical studies evaluat-
ing the hemostatic efficacy of rFVIIa treatment in inhibitor-
expressing patients with hemophilia A or B. The total number 
of patients treated was 256, with the majority of studies enroll-
ing fewer than 30 patients. This small sample size significantly 
limited the ability to form conclusions about the efficacy and 
safety of rFVIIa treatment in these patients. Specifically, 
6 studies evaluated different doses of rFVIIa in surgical and 
at-home treatment settings,11,15–17,20,21 and 2 studies compared 
the efficacy of rFVIIa with that of FEIBA.18,21
Dose evaluation
With regard to the optimal dose of rFVIIa, initial studies 
evaluated low doses in patients undergoing surgery (35 vs 
90 µg/kg)15 and in patients with joint, muscular, and muco-
cutaneous bleeding (35 vs 70 µg/kg).11 More recent research 
has compared repeated doses of 90 µg/kg rFVIIa with 
single doses of 270 µg/kg rFVIIa in an at-home treatment 
setting.16,17,21 Shapiro et al15 reported that high-dose rFVIIa 
(90 µg/kg) administered to patients undergoing surgery 
exhibited 93% hemostatic efficacy compared with 67% 
efficacy presented by the low-dose (35 µg/kg) group, and 
the efficacy in these 2 groups varied significantly beginning 
postoperative day 3. Additionally, 5 patients were found to 
have   hemostatic   treatment failures, requiring an “escape” dose 
of up to 180 µg/kg rFVIIa or alternative hemostatic therapy 
and also leaving the study group. All of these patients except 
one were in the low-dose group, and it was concluded that the 
dose of 90 µg/kg rFVIIa was appropriate for surgical inter-
ventions. This finding was recently challenged by Obergfell 
et al,22 who reviewed published data on elective orthopedic 
surgical procedures in inhibitor-expressing patients with 
hemophilia from January 2002 to November 2006. They 
found that most bleeding complications could be resolved 
by increasing the rFVIIa dose or administering an extra dose 
and concluded that the optimal initial rFVIIa bolus dose for 
orthopedic surgery may be higher than 90 µg/kg. Furthermore, 
in the major orthopedic interventions reported by Solimeno 
et al23 and Rodriguez-Merchan et al,24 bleeding complications 
were only observed in patients receiving the dose of 90 µg/
kg rFVIIa. Based on these data, a minimum initial dose of 
120 µg/kg rFVIIa, followed by a similar or 90 µg/kg dose 
every 2 hours, was suggested for patients in the BI group.22
At-home treatment
With regard to the at-home treatment of joint bleeds in hemo-
philic patients with coagulation-factor inhibitors, 4 RCTs 
have been reported. Lusher et al11 evaluated low-dose rFVIIa 
(35 vs 70 µg/kg), with approximately 60% of patients in 
each group reporting excellent efficacy for the treatment of 
joint bleeds. Later investigations of joint bleeds compared a 
single high dose of rFVIIa (270 µg/kg) with a standard dose 
of rFVIIa (90 µg/kg) every 3 hours.16,17,21 With regard to 
hemostatic efficacy, no significant differences were observed 
between treatment groups in any of the studies. The percent-
age of patients reporting a successful response to rFVIIa 
treatment varied from 31% to 66%, which is well below the 
80%–90% efficacy rating reported in the literature for non-
randomized trials.10,25 The percentages are also lower than 
that reported by Goldstein et al,26 who determined that rFVIIa 
treatment administered by the Hemophilia and Thrombosis 
Research Society from 2000 to 2008 was effective in 74% 
of adult patients. The reason for this discrepancy is unclear 
because RCTs and observational studies are generally 
expected to yield similar efficacies.27,28 However, the high 
hemostatic efficacy of rFVIIa reported in the nonrandomized 
observational studies may be because such studies are more 
likely to include a broad range of patients with coexisting 
illnesses, a wide spectrum of disease severity, and treatment 
tailored to the individual. Because the risk profile of the 
patient affects the choice of drug, confounding variables may 
be introduced by different treatment regimens. In contrast, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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RCTs typically enroll patients who are highly selected, 
considered fit to enter the trial, likely to finish the trial, and 
believed or demonstrated to comply with medication. This 
patient population is quite different from that encountered 
during routine clinical practice. Furthermore, the low number 
of subjects included in the RCTs reported here11,16,17,21 may 
also explain the broader and thus less precise efficacy ranges 
compared with larger observational studies that include more 
subjects.10,25
Administration of a single high dose of rFVIIa offers 
many advantages, such as less pain and reduced number of 
needle sticks and infusions. Additionally, single high-dose 
administration may facilitate patient compliance and improve 
the feasibility of at-home treatment or self-administration. 
At-home treatment itself can facilitate early intervention, 
resulting in increased treatment efficacy due to decreased 
intervention time.25 No significant difference in hemostatic 
efficacy, as evaluated by grading the patients’ perception of 
pain and mobility following rFVIIa treatment16,17,21 and/or 
by the need for rescue medication,17,21 was found between 
repeated standard-dose and single high-dose rFVIIa admin-
istration in the RCTs reported here. As a result, high-dose 
rFVIIa (270 µg/kg) was approved by the EMEA in 2007. 
It should be noted, however, that 3 RCTs performed till 
date only involved 67 patients in total, making it difficult to 
exclude the possibility that a significant difference actually 
exists between the treatment regimes.
Bolus vs Ci
One study compared repeated BIs of rFVIIa with CI in 
24 inhibitor-expressing hemophilic patients undergoing major 
orthopedic surgery.20 It was found that the hemostatic efficacy 
at the end of the study was comparable for perioperative 
BI and CI (73% and 75%, respectively). As predicted, the 
dosing schedule of rFVIIa resulted in different daily and 
cumulative doses in the CI and BI groups; during and up 
to 72 hours after the operation, the dose was greater in the 
CI group than in the BI group (292.2 vs 237.5 mg, respectively). 
The treatment efficacy reported by Pruthi et al20 is somewhat 
lower than that reported by Ludlam et al,29 who reported a 
hemostatic efficacy of 89% in 9 inhibitor-expressing patients 
undergoing major surgery and treated the patients with the 
same dosing scheme as that of the CI group. It should be 
noted, however, that 4 of 9 patients received tranexamic 
acid. Similarly, Santagostino et al30 described 11 inhibitor-
expressing patients undergoing major surgery who received 
a CI dose of only 20 µg/kg rFVIIa per hour together with 
tranexamic acid, demonstrating hemostatic efficacy in 9 of 
the 11 patients (81%). In contrast, Smith et al31 used a fixed 
dose of 16.5 µg/kg rFVIIa per hour without tranexamic acid 
and reported a hemostatic efficacy of only 33%. From these 
data, we can conclude that CI at a dose of 50 µg/kg rFVIIa 
per hour after a standard bolus dose of rFVIIa results in an 
acceptable hemostatic efficacy. Additionally, it may be ben-
eficial to consider adjunctive treatment with tranexamic acid. 
An RCT comparing the hemostatic efficacy of CI alone and 
CI in conjunction with tranexamic acid is, thus, warranted.
rFviia vs FeiBA (aPCC) treatment
Two of the reviewed studies compared rFVIIa with FEIBA 
as an at-home treatment in inhibitor-expressing patients with 
joint bleeds.18,21 When comparing the hemostatic efficacy of 
a standard dose of rFVIIa (90 µg/kg) infused 218 or 3 times21 
with that of a single dose of FEIBA (75–100 IU/kg), highly 
different results emerge. In the study by Astermark et al18, 
2 treatments resulted in a similar hemostatic efficacy (81% for 
FEIBA vs 79% for rFVIIa), whereas Young et al21 reported 
a successful response, as evaluated by the need for rescue 
medication, in only 54% of the FEIBA-treated patients 
compared with 91%–92% in the rFVIIa-treated patients. 
The difference in the response to rFVIIa between the 2 stud-
ies may be partly explained by different dosing schedules. 
The patients examined by Young et al21 received 3 doses at 
3-hour intervals, while those of the Astermark et al18 study 
received only 2 doses. With an estimated rFVIIa half-life of 
approximately 120 minutes, 3 doses would result in higher 
peak thrombin generation, maintaining elevated thrombin 
levels for a longer time than 2 doses.
However, the reason for the different hemostatic response 
to FEIBA reported by 2 research groups is less obvious. 
The hemostatic efficacy of FEIBA has previously been 
observed to vary from 80% to nearly 100% under different 
conditions, including at-home treatment of spontaneous or 
traumatic bleeds and major and minor surgery.32–34   Possible 
explanations for the discrepancy in treatment efficacy 
observed between RCTs and observational studies may 
involve different study populations, as mentioned earlier. 
Differences in dose and dosing frequency, ancillary hemo-
static therapy, efficacy criteria, and time points at which 
efficacy was evaluated may also contribute significantly 
to the observed discrepancies.21,32–34 Furthermore, it could 
be argued that because the standard recommended dose of 
FEIBA is 50–100 IU/kg every 4–6 hours, and the standard 
dose of rFVIIa is 90 µg/kg every 2–3 hours until hemostasis 
is achieved, the doses administered to the FEIBA and rFVIIa 
treatment groups were markedly unmatched. This is because Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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the treatment efficacy depends on the administered dose of 
FEIBA.34 This was illustrated in 6 hemophilic patients with 
coagulation-factor inhibitors who experienced 61 bleeds that 
were treated with FEIBA. Definite cessation of bleeding was 
demonstrated in 93% of the patients receiving a cumulative 
median dose of 205 IU/kg per event.34 The authors observed 
that FEIBA treatment stopped the hemorrhaging later than 
rFVIIa treatment but resulted in a lower number of rebleed-
ing episodes.34
rFviia for secondary prophylaxis
One group compared the effect of 90 and 270 µg/kg rFVIIa 
on bleeding frequency for secondary prophylaxis in inhibitor-
  expressing patients with frequent bleeding episodes.19 Bleed-
ing frequency was essentially halved during the 3-month 
prophylaxis using 2 doses of rFVIIa when compared with that 
during the 3-month preprophylaxis period (median value for 
target joint bleeds per 3 months, 11.5 vs 4 for 90 µg/kg dose 
and 9 vs 2.5 for 270 µg/kg dose, both P , 0.001). Intrigu-
ingly, the reduction in bleeding frequency persisted during the 
3-month postprophylaxis period (median value for target joint 
bleeds per 3 months, 5 for 90 µg/kg dose and 5 for 270 µg/kg 
dose, both P , 0.01), and it was suggested that this reduc-
tion may be due to a reduction in the inflammation associ-
ated with chronic synovitis. Although secondary   prophylaxis 
appears to be a promising alternative to on-demand therapy 
in hemophilic patients lacking inhibitors,35,36 evidence sup-
porting secondary prophylaxis over on-demand treatment 
was previously derived from small observational studies 
and clinical case reports. Although several case reports 
describe an excellent response to secondary rFVIIa-based 
prophylaxis in patients with high titers of inhibitors suffering 
from frequent bleeding,37–39 there is little scientific evidence 
supporting the efficacy of such therapy, besides the RCT 
presented here.19
Treatment efficacy evaluation
As outlined above, considerable difficulty exists in evaluat-
ing rFVIIa treatment in inhibitor-expressing patients with 
hemophilia. This is due to the apparent lack of standardiza-
tion in the evaluation of hemostatic efficacy. For the at-home 
treatment setting,11,16–18,21 treatment success was evaluated 
by the patients themselves in 4 studies,16–18,21 whereas the 
efficacy was judged by the investigators in 1 study.11 Another 
investigation used the patients’ perception of whether the 
treatment was effective, partially effective, poorly effective, 
or not effective and if the bleeding had stopped.18 Meanwhile, 
the remaining 3 studies graded the patients’ perception of 
pain and mobility following rFVIIa treatment.16,17,21 Two of 
the studies additionally used the need for rescue medication 
as a marker of effectiveness.17,21 Also, different time points 
for the evaluation of hemostatic efficacy were used, with 
1 group using 6 hours,18 1 using over 8 hours,11 and 3 using 
9 hours,16,17,21 after the first rFVIIa treatment. With regard 
to studies evaluating the hemostatic efficacy of rFVIIa in 
surgical procedures, the 2 studies presented here based the 
evaluation on the investigators’ assessment at discontinua-
tion of therapy or at postoperative day 1020 or the need for an 
escape dose of rFVIIa during the study.15 The considerable 
heterogeneity in the assessment of hemostatic efficacy and in 
sampling time points is in agreement with reports from non-
randomized studies.10,22–25,32–34,37–39 Obviously, this constitutes 
a significant problem for the interpretation and comparison 
of results from the studies of patients with hemophilia. Thus, 
data interpretation and the comparison of efficacy in the 
future studies on patients with hemophilia would be improved 
if efficacy parameters were standardized.
rFviia and adverse  
thromboembolic events
Concern about the potential risk of thromboembolic events 
secondary to rFVIIa administration has been discussed.40,41 In 
8 studies reviewed here, 2 reported adverse thromboembolic 
events.15,20 In the study by Shapiro et al,15 1 patient in the 
35 µg/kg rFVIIa-treated group developed thrombosis of the 
right internal jugular vein on the second day following cen-
tral venous catheter placement. Meanwhile, in the study by 
Pruthi et al,20 1 patient in the BI group developed thrombosis 
of the popliteal and proximal peroneal veins, documented by 
  Doppler ultrasonography on day 10 after surgery. Additionally, 
2 reviews reported adverse thromboembolic events following 
rFVIIa treatment in patients with hemophilia from 1996 to April 
200342 and from May 2003 to 2006.43 In total, 55 thromboem-
bolic events are reported among approximately 1.5 million 
standard doses (90 µg/kg) administered to a 40-kg individual. 
Given these data, the number of thromboembolic events in this 
patient population is approximately 3.67 per 100,000 infusions, 
which is quite low. Consequently, rFVIIa administration to 
inhibitor-expressing patients with hemophilia appears safe 
due to a lower incidence of thromboembolic events than that 
reported for other clotting factor concentrates.42,43
Congenital platelet deficiencies
No RCTs describing the safety and efficacy of rFVIIa treat-
ment in patients with congenital platelet disorders exist. Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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A number of reports suggest that rFVIIa administration to 
patients with Glanzmann’s thrombasthenia and Bernard 
Souliers syndrome may be beneficial, while others do not 
support its clinical use.44 As rFVIIa is only administered to 
patients with congenital platelet disorders when other treat-
ment options fail, this may justify its use despite the lack of 
scientific evidence.
It is worrisome that rFVIIa treatment in clotting factor 
inhibitor – expressing patients with hemophilia is based on 
weight alone. Furthermore, because there is a consensus 
among the scientific community that the coagulopathy in 
hemophilia is related to impaired thrombin generation, it is 
surprising to find that assays only reflecting 2%–3% of the 
patient’s ability to generate thrombin, such as activated partial 
thromboplastin time (aPTT) and prothrombin time, are used. 
These plasma-based coagulation tests were developed more 
than 50 years ago, when it was believed that the hemostatic 
process could be explained by the clotting cascade.45,46 Fur-
thermore, they are developed to monitor anticoagulation and 
have consistently been shown to correlate poorly with clinical 
bleeding conditions.47–56
A cell-based model of hemostasis was introduced in 
1994, emphasizing the importance of both platelets and 
tissue factor (TF), an initiator of coagulation, for proper 
hemostasis.57,58 The coagulation process involves the fol-
lowing 3 phases: initiation, amplification, and propagation. 
During initiation, circulating FVIIa forms a complex with 
exposed TF on a TF-bearing cell. This complex converts 
FIX and FX into their active forms, FIXa and FXa, respec-
tively. During the amplification, the FXa-activated factor 
V (FVa) – TF complex acts on prothrombin to generate a 
small amount of thrombin that is responsible for initiat-
ing several events, including platelet activation. Finally, 
propagation takes place on the surface of the activated 
platelet, where FVa and FVIIIa are bound. FIX and FX 
are converted to FIXa and FXa, respectively, forming the 
tenase and prothrombinase complexes, respectively, which 
rapidly generate a large “thrombin burst.” The kinetics of 
this burst influence clot strength and stability by activating 
FXIII to FXIIIa and TAFI to TAFIa in a concentration-
dependent manner.59 Consequently, assays reflecting the 
patient’s ability to generate thrombin are preferable for 
monitoring hemostasis.
Whole-blood viscoelastic assays, such as thromboelas-
tography (TEG®; Haemoscope Corp., Niles, Illinois, USA) 
and rotational thromboelastometry (ROTEM®; Munich, 
Germany), have consistently been shown to be superior 
to conventional plasma-based coagulation assays for 
  predicting the need for blood transfusion in patients with 
severe   bleeding, as well as, for directing the treatment with 
plasma and platelets in nonhemophilic patients.51–54,60–71 
The scientific rationale for this superiority was delin-
eated by Rivard et al,72 who demonstrated a correlation 
between total thrombus generation over a period of time, 
as evaluated by TEG, and the concentration of generated 
thrombin–antithrombin complexes. Coagulation-factor 
deficiency and/or t  hrombocytopenia/pathy likely results in 
impaired thrombin generation, thus reducing the clot forma-
tion and stability, which is indicated by an abnormal TEG 
tracing.51–54,60–70,73,74 Given this, it seems rationale to monitor 
hemostasis in inhibitor-expressing patients with hemophilia 
by TEG/ROTEM, as suggested by Yoshioka et al73 over 
10 years ago and by Sorensen and Ingerslev74 more recently. 
This is supported by Bassus et al,75 who found that the 
administration of FVIII concentrate in patients with hemo-
philia A correlated linearly with increased FVIII activity, as 
evaluated by aPTT. On the contrary, thrombin generation and 
maximal clot strength, evaluated by the thrombin generation 
test (TGT) and TEG, showed no such correlation. Instead, 
substituting whole-blood samples ex vivo with 1 U/mL FVIII 
resulted in maximal hemostatic effect of FVIII, as evaluated 
by both TGT and TEG maximal clot strength. It also became 
evident that 30% FVIII activity was sufficient to achieve 
more than 90% of maximal thrombin generation and clot 
strength. Additionally, FVIII substitution up to a plasma 
activity level greater than 90% did not further enhance 
the hemostatic effect. With regard to inhibitor-expressing 
patients, Trowbridge et al76 also reported the successful use 
of TEG to guide the administration of rFVIIa to patients 
with hemophilia, who were difficult to manage based on 
conventional plasma-based coagulation assays.
The systematic use of viscoelastic whole-blood assays 
has the potential to significantly improve the treatment of 
inhibitor-expressing patients with hemophilia. Instead of 
administering rFVIIa at doses related to patient weight, an 
individual dosing regimen based on the amount of FVIIa 
needed to establish maximal thrombin generation and clot 
strength seems preferable.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Oldenburg J, Dolan G, Lemm G. Haemophilia care then, now and in the 
future. Haemophilia. 2009;15(Suppl 1):S2–S7.
2.  Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. 
Haemophilia. 2002;8:280–287.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
115
rFviia in congenital bleeding disorders
  3.  Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in 
haemophiliacs: a single-centre experience over 34 years, 1964-97. Br 
J Haematol. 1999;104:909–914.
  4.  Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development 
in previously untreated patients with hemophilia A: a prospective 
  long-term follow-up comparing plasma-derived and recombinant 
products. Semin Thromb Hemost. 2002;28:285–290.
  5.  Goodeve A. The incidence of inhibitor development according to spe-
cific mutations – and treatment? Blood Coagul Fibrinolysis. 2003;14 
(Suppl 1):S17–S21.
  6.  Morfini M, Haya S, Tagariello G, et al. European study on ortho-
paedic status of haemophilia patients with inhibitors. Haemophilia. 
2007;13:606–612.
  7.  Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. The effect 
of activated prothrombin-complex concentrate (FEIBA) on joint and 
muscle bleeding in patients with hemophilia A and antibodies to 
factor VIII. A double-blind clinical trial. N Engl J Med. 1981;305: 
717–721.
  8.  Hedner U. Mechanism of action, development and clinical experience 
of recombinant FVIIa. J Biotechnol. 2006;124:747–757.
  9.  Pan-Petesch B, Laguna P, Mital A, et al. Single-dose (270 microg kg(-1)) 
recombinant activated factor VII for the treatment and prevention of 
bleeds in haemophilia A patients with inhibitors: experience from seven 
European haemophilia centres. Haemophilia. 2009;15:760–765.
  10.  Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild 
to moderate bleeding episodes using recombinant factor VIIa 
  (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost. 1998; 
80:912–918.
  11.  Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-
blind comparison of two dosage levels of recombinant factor VIIa in 
the treatment of joint, muscle and mucocutaneous haemorrhages in 
persons with haemophilia A and B, with and without inhibitors. rFVIIa 
study group. Haemophilia. 1998;4:790–798.
  12.  Laurian Y, Goudemand C, Négrier C, et al. Use of recombinant activated 
factor VII as first-line therapy for bleeding episodes in haemophiliacs 
with factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul 
Fibrinolysis. 1998;9:S155–S156.
  13.  Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of 
high-dose factor VIIa is independent of tissue factor. Br J Haematol. 
1997;99:542–547.
  14.  Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by 
recombinant factor VIIa in plasma from patients with severe hemophilia A.   
Blood. 2002;99:175–179.
  15.  Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised 
trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with 
inhibitors undergoing surgery. Thromb Haemost. 1998;80:773–778.
  16.  Santagostino E, Mancuso ME, Rocino A, et al. A prospective random-
ized trial of high and standard dosages of recombinant factor VIIa for 
treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb 
Haemost. 2006;4:367–371.
  17.  Kavakli K, Makris M, Zulfikar B, et al. Home treatment of haemar-
throses using a single dose regimen of recombinant activated factor VII 
in patients with haemophilia and inhibitors. A multi-centre, randomised, 
double-blind, cross-over trial. Thromb Haemost. 2006;95:600–605.
  18.  Astermark J, Donfield SM, DiMichele DM, et al. A randomized 
comparison of bypassing agents in hemophilia complicated by an 
inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 
2007;109:546–551.
  19.  Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospec-
tive clinical trial of recombinant factor VIIa for secondary prophy-
laxis in hemophilia patients with inhibitors. J Thromb Haemost. 
2007;5:1904–1913.
  20.  Pruthi RK, Mathew P, Valentino LA, et al. Haemostatic efficacy and 
safety of bolus and continuous infusion of recombinant factor VIIa are 
comparable in haemophilia patients with inhibitors undergoing major 
surgery. Results from an open-label, randomized, multicenter trial. 
Thromb Haemost. 2007;98:726–732.
  21.  Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-
dose rFVIIa vs standard 90 microg kg(-1)-dose rFVIIa and APCC for 
home treatment of joint bleeds in haemophilia patients with inhibitors: 
a randomized comparison. Haemophilia. 2008;14:287–294.
  22. Obergfell A, Auvinen MK, Mathew P. Recombinant activated fac-
tor VII for haemophilia patients with inhibitors undergoing ortho-
paedic surgery: a review of the literature. Haemophilia. 2008;14: 
233–241.
  23.  Solimeno LP, Perfetto OS, Pasta G, Santagostino E. Total joint 
replacement in patients with inhibitors. Haemophilia. 2006;12 
(Suppl 3):113–116.
  24.  Rodriguez-Merchan EC, Wiedel JD, Wallny T, et al. Elective ortho-
paedic surgery for inhibitor patients. Haemophilia. 2003;9:625–631.
  25.  Santagostino E, Gringeri A, Mannucci PM. Home treatment with 
recombinant activated factor VII in patients with factor VIII inhibi-
tors: the advantages of early intervention. Br J Haematol. 1999;104: 
22–26.
  26.  Goldstein B, Geldziler B, Bjerre J, Seremetis S. Evidence-based use 
of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of 
hemophilia with inhibitors in children and adolescents. Transfus Apher 
Sci. 2008;38:25–32.
  27.  Hotchkiss RS, Tinsley KW, Swanson PE, Karl IE. Endothelial cell 
apoptosis in sepsis. Crit Care Med. 2002;30:S225–S228.
  28.  Doshi SN, Marmur JD. Evolving role of tissue factor and its pathway 
inhibitor. Crit Care Med. 2002;30:S241–S250.
  29.  Ludlam CA, Smith MP, Morfini M, et al. A prospective study of 
recombinant activated factor VII administered by continuous infu-
sion to inhibitor patients undergoing elective major orthopaedic 
surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol. 
2003;120:808–813.
  30.  Santagostino E, Morfini M, Rocino A, et al. Relationship between fac-
tor VII activity and clinical efficacy of recombinant factor VIIa given 
by continuous infusion to patients with factor VIII inhibitors. Thromb 
Haemost. 2001;86:954–958.
  31.  Smith MP, Ludlam CA, Collins PW, et al. Elective surgery on fac-
tor VIII inhibitor patients using continuous infusion of recombinant 
activated factor VII: plasma factor VII activity of 10 IU/mL is asso-
ciated with an increased incidence of bleeding. Thromb Haemost. 
2001;86:949–953.
  32.  Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study 
on the utilization of FEIBA in France in patients with factor VIII and 
factor IX inhibitors. French FEIBA Study Group. Factor eight bypassing 
activity. Thromb Haemost. 1997;77:1113–1119.
  33.  Dimichele D, Negrier C. A retrospective postlicensure survey of FEIBA 
efficacy and safety. Haemophilia. 2006;12:352–362.
  34.  Smejkal P, Brabec P, Matyskova M, et al. FEIBA in treatment of 
acute bleeding episodes in patients with haemophilia A and factor 
VIII inhibitors: a retrospective survey in regional haemophilia centre. 
Haemophilia. 2009;15:743–751.
  35.  Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study 
of orthopaedic outcomes for severe factor-VIII-deficient haemo-
philiacs. The Orthopaedic Outcome Study Group. J Intern Med. 
1994;236:391–399.
  36.  Szucs TD, Offner A, Kroner B, et al. Resource utilisation in haemo-
philiacs treated in Europe: results from the European study on socio-
economic aspects of haemophilia care. The European Socioeconomic 
Study Group. Haemophilia. 1998;4:498–501.
  37.  Cooper HA, Jones CP, Campion E, et al. Rationale for the use of high 
dose rFVIIa in a high-titre inhibitor patient with haemophilia B during 
major orthopaedic procedures. Haemophilia. 2001;7:517–522.
  38.  Young G, McDaniel M, Nugent DJ. Prophylactic recombinant fac-
tor VIIa in haemophilia patients with inhibitors. Haemophilia. 
2005;11:203–207.
  39.  Morfini M, Auerswald G, Kobelt RA, et al. Prophylactic treatment of 
haemophilia patients with inhibitors: clinical experience with recom-
binant factor VIIa in European haemophilia centres. Haemophilia. 
2007;13:502–507.Drug Design, Development and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
Drug Design, Development and Therapy is an international, peer-
reviewed open-access journal that spans the spectrum of drug design 
and development through to clinical applications. Clinical outcomes, 
patient safety, and programs for the development and effective, safe, 
and sustained use of medicines are a feature of the journal, which 
has also been accepted for indexing on PubMed Central. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
116
Johansson and Ostrowski
  40.  Aledort LM. Comparative thrombotic event incidence after infusion of 
recombinant factor VIIa versus factor VIII inhibitor bypass activity.   
J Thromb Haemost. 2004;2:1700–1708.
  41.  O’Connell NM, Riddell AF, Pascoe G, et al. Recombinant factor VIIa 
to prevent surgical bleeding in factor XI deficiency. Haemophilia. 
2008;14:775–781.
  42.  Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dos-
ing regimens and safety in patients with congenital and acquired factor 
VIII or IX inhibitors. J Thromb Haemost. 2004;2:899–909.
  43.  Abshire T, Kenet G. Safety update on the use of recombinant factor 
VIIa and the treatment of congenital and acquired deficiency of factor 
VIII or IX with inhibitors. Haemophilia. 2008;14:898–902.
  44.  Franchini M. The use of recombinant activated factor VII in plate-
let disorders: a critical review of the literature. Blood Transfus. 
2009;7:24–28.
  45.  Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. 
Science. 1964;145:1310–1312.
  46.  MacFarlane RG. An enzyme cascade in the blood clotting mecha-
nism, and its function as a biochemical amplifier. Nature. 1964; 
202:498–499.
  47.  Aoki N, Wall MJ, Demsar J, et al. Predictive model for survival at 
the conclusion of a damage control laparotomy. Am J Surg. 2000; 
180:540–544.
  48.  Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy.   
J Trauma. 2003;54:1127–1130.
  49.  MacLeod JB, Lynn M, McKenney MG, et al. Early coagulopathy 
predicts mortality in trauma. J Trauma. 2003;55:39–44.
  50.  Martini WZ, Cortez DS, Dubick MA, et al. Thrombelastography is 
better than PT, aPTT, and activated clotting time in detecting clinically 
relevant clotting abnormalities after hypothermia, hemorrhagic shock 
and resuscitation in pigs. J Trauma. 2008;65:535–543.
  51.  Plotkin AJ, Wade CE, Jenkins DH, et al. A reduction in clot forma-
tion rate and strength assessed by thrombelastography is indicative of 
transfusion requirements in patients with penetrating injuries. J Trauma. 
2008;64(Suppl 2):S64–S68.
  52.  Gravlee GP, Arora S, Lavender SW, et al. Predictive value of blood 
clotting tests in cardiac surgical patients. Ann Thorac Surg. 1994; 
58:216–221.
  53.  Segal JB, Dzik WH. Paucity of studies to support that abnormal coagula-
tion test results predict bleeding in the setting of invasive procedures: 
an evidence-based review. Transfusion. 2005;45:1413–1425.
  54.  Murray D, Pennell B, Olson J. Variability of prothrombin time and 
activated partial thromboplastin time in the diagnosis of increased 
surgical bleeding. Transfusion. 1999;39:56–62.
  55.  Shapiro S, Sherwin B, Gordimer H. Postoperative thrombo- 
embolization: the platelet count and the prothrombin time after surgical 
operations: a simple method for detecting reductions and elevations of 
the prothrombin concentration (or activity) of the blood plasma. Ann 
Surg. 1942;116:175–183.
  56.  Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. 
A simple screening test for first stage plasma clotting factor deficiencies. 
Am J Clin Pathol. 1961;36:212–219.
  57.  Monroe DM, Roberts HR, Hoffman M. Platelet procoagulant com-
plex assembly in a tissue factor-initiated system. Br J Haematol. 
1994;88:364–371.
  58.  Monroe DM, Hoffman M. What does it take to make the perfect clot? 
Arterioscler Thromb Vasc Biol. 2006;26:41–48.
  59.  Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 
2007;21:131–142.
  60.  Kang YG, Martin DJ, Marquez J, et al. Intraoperative changes in blood 
coagulation and thrombelastographic monitoring in liver transplanta-
tion. Anesth Analg. 1985;64:888–896.
  61.  McNicol PL, Liu G, Harley ID, et al. Patterns of coagulopathy during 
liver transplantation: experience with the first 75 cases using thrombe-
lastography. Anaesth Intensive Care. 1994;22:659–665.
  62.  Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion 
therapy and reexploration rate after institution of a blood management 
program in cardiac surgical patients. J Cardiothorac Vasc Anesth. 
1995;9:168–173.
  63.  Shore-Lesserson  L,  Manspeizer  HE,  DePerio  M,  et  al.   
Thromboelastography-guided transfusion algorithm reduces transfu-
sions in complex cardiac surgery. Anesth Analg. 1999;88:312–319.
  64.  Manikappa S, Mehta Y, Juneja R, Trehan N. Changes in transfusion 
therapy guided by thromboelastograph in cardiac surgery. Ann Card 
Anaesth. 2001;4:21–27.
  65.  Anderson L, Quasim I, Soutar R, et al. An audit of red cell and blood 
product use after the institution of thromboelastometry in a cardiac 
intensive care unit. Transfus Med. 2006;16:31–39.
  66.  Welsby IJ, Jiao K, Ortel TL, et al. The kaolin-activated thrombelas-
tograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc 
Anesth. 2006;20:531–535.
  67.  Kaufmann CR, Dwyer KM, Crews JD, et al. Usefulness of thrombe-
lastography in assessment of trauma patient coagulation. J Trauma. 
1997;42:716–720.
  68.  Johansson PI. Treatment of massively bleeding patients: introducing 
real-time monitoring, transfusion packages and thrombelastography 
(TEGR). ISBT Sci Ser. 2007;2:159–167.
  69.  Johansson PI, Bochsen L, Stensballe J, Secher NH. Transfusion pack-
ages for massively bleeding patients: the effect on clot formation and 
stability as evaluated by Thrombelastograph (TEG(R)). Transfus Apher 
Sci. 2008;39:3–8.
  70.  Johansson PI, Stensballe J. Effect of haemostatic control resuscitation 
on mortality in massively bleeding patients: a before and after study. 
Vox Sang. 2009;96:111–118.
  71.  Johansson PI, Stissing T, Bochsen L, Ostrowski SR. Thrombelastogra-
phy and tromboelastometry in assessing coagulopathy in trauma. Scand 
J Trauma Resusc Emerg Med. 2009;17:45.
  72.  Rivard GE, Brummel-Ziedins KE, Mann KG, et al. Evaluation of 
the profile of thrombin generation during the process of whole blood 
clotting as assessed by thrombelastography. J Thromb Haemost. 
2005;3:2039–2043.
  73.  Yoshioka A, Nishio K, Shima M. Thrombelastgram as a hemostatic 
monitor during recombinant factor VIIa treatment in hemophilia A 
patients with inhibitor to factor VIII. Haemostasis. 1996;26:139–142.
  74.  Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient 
requirements – an update on monitoring haemostatic response using 
thrombelastography. Haemophilia. 2005;11(Suppl 1):1–6.
  75.  Bassus S, Wegert W, Krause M, et al. Platelet-dependent coagulation 
assays for factor VIII efficacy measurement after substitution therapy 
in patients with haemophilia A. Platelets. 2006;17:378–384.
  76.  Trowbridge CC, Stammers AH, Ciccarelli N, Klayman M. Dose titration 
of recombinant factor VIIa using thromboelastograph monitoring in a 
child with hemophilia and high titer inhibitors to factor VIII: a case 
report and brief review. J Extra Corpor Technol. 2006;38:254–259.